All lobbying filings

APOTEX CORP.

APOTEX CORP. filed a Q2 report for APOTEX CORP. on July 20, 2026.

Lobbying for APOTEX CORP.

All filings by APOTEX CORP. · Everything APOTEX CORP. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$730,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Florida

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Manufacturing

Federal policy relating to providing federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; and Federal policy relating to amending Hatch-Waxman Act 180-day exclusivity eligibility to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations.

Trade (domestic/foreign)

Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain.

HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.

Health Issues

HR 5526/S. 1954, the Biosimilar Red Tape Elimination Act, provisions relating to deeming a biosimilar interchangeable with its reference product immediately upon approval.

Bills named in this filing 4

H.R. 6485
Skinny Labels, Big Savings Act
S. 43
Skinny Labels, Big Savings Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1954
Biosimilar Red Tape Elimination Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.